Availability, relative prices, and territorial inequality of essential medicines in Peru: a pharmaceutical surveillance analysis using official sources, 2020–2025

Background/Objectives National pharmaceutical surveillance can describe medicine availability and relative prices, but it cannot establish household affordability without treatment-cost and purchasing-power data. We assessed recorded availability, national relative prices, and territorial inequality of essential medicines in Peru during 2020–2025.Methods An ecological annual panel integrated 363,183 administrative records; 311,020 were classified as essential medicines. Descriptive analyses, two-way cluster-robust modified Poisson models, and sensitivity analyses addressed repeated observations, missing prices, unspecified care levels, and changes in the product basket.Results Median recorded availability increased from 85.4% in 2020–99.4% in 2025; the proportion below 80% decreased from 47.5% to 36.5%. Excluding unspecified care levels reduced the overall low-availability proportion from 44.9% to 27.4%. Prices were linked for 42.9% of essential-medicine records, and 9.6% of linked records had high relative prices. Low availability and high relative price co-occurred in 4.8% of linked records. Availability Gini declined from 0.082 to 0.037, whereas co-occurrence Gini was 0.262 in 2025 despite a lower mean co-occurrence burden. The East had higher adjusted low-availability prevalence than Center (aPR 1.20; 95% CI 1.08–1.34). Improvement after 2023 persisted in a balanced panel but was attenuated after excluding unspecified care levels.Conclusion Recorded availability improved, with substantial sensitivity to administrative composition. Incomplete and ingredient-level price linkage limits economic interpretation; the findings support targeted surveillance, not conclusions about patient affordability or causal policy effects.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Policy and Practice
Published
2026-11-18
DOI
https://doi.org/10.1080/20523211.2026.2761150
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Availability, relative prices, and territorial inequality of essential medicines in Peru: a pharmaceutical surveillance analysis using official sources, 2020–2025

Victor Moreno-Prieto, Junior F. Siguas-Peña, María Andrea Serrano Boza, Camila Alessandra Vasquez Ramirez
3 links
Journal of Pharmaceutical Policy and Practice
Pharmaceutical Economics and Policy
article

Availability, relative prices, and territorial inequality of essential medicines in Peru: a pharmaceutical surveillance analysis using official sources, 2020–2025

Victor Moreno-Prieto, Junior F. Siguas-Peña, María Andrea Serrano Boza, Camila Alessandra Vasquez Ramirez
article en

Abstract

Background/Objectives National pharmaceutical surveillance can describe medicine availability and relative prices, but it cannot establish household affordability without treatment-cost and purchasing-power data. We assessed recorded availability, national relative prices, and territorial inequality of essential medicines in Peru during 2020–2025.Methods An ecological annual panel integrated 363,183 administrative records; 311,020 were classified as essential medicines. Descriptive analyses, two-way cluster-robust modified Poisson models, and sensitivity analyses addressed repeated observations, missing prices, unspecified care levels, and changes in the product basket.Results Median recorded availability increased from 85.4% in 2020–99.4% in 2025; the proportion below 80% decreased from 47.5% to 36.5%. Excluding unspecified care levels reduced the overall low-availability proportion from 44.9% to 27.4%. Prices were linked for 42.9% of essential-medicine records, and 9.6% of linked records had high relative prices. Low availability and high relative price co-occurred in 4.8% of linked records. Availability Gini declined from 0.082 to 0.037, whereas co-occurrence Gini was 0.262 in 2025 despite a lower mean co-occurrence burden. The East had higher adjusted low-availability prevalence than Center (aPR 1.20; 95% CI 1.08–1.34). Improvement after 2023 persisted in a balanced panel but was attenuated after excluding unspecified care levels.Conclusion Recorded availability improved, with substantial sensitivity to administrative composition. Incomplete and ingredient-level price linkage limits economic interpretation; the findings support targeted surveillance, not conclusions about patient affordability or causal policy effects.

Journal of Pharmaceutical Policy and PracticeVol. 19(1)
Universidad Norbert Wiener (PE)
Reduced inequalities, Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon